[go: up one dir, main page]

FI109207B - Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja - Google Patents

Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja Download PDF

Info

Publication number
FI109207B
FI109207B FI935970A FI935970A FI109207B FI 109207 B FI109207 B FI 109207B FI 935970 A FI935970 A FI 935970A FI 935970 A FI935970 A FI 935970A FI 109207 B FI109207 B FI 109207B
Authority
FI
Finland
Prior art keywords
antibody
tyr
cell line
antigen
leu
Prior art date
Application number
FI935970A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI935970A0 (fi
FI935970L (fi
Inventor
Jan Holmgren
Peter Lind
Leif Lindholm
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of FI935970A0 publication Critical patent/FI935970A0/fi
Publication of FI935970L publication Critical patent/FI935970L/fi
Application granted granted Critical
Publication of FI109207B publication Critical patent/FI109207B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI935970A 1991-07-03 1993-12-31 Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja FI109207B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9102074 1991-07-03
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody
PCT/SE1992/000502 WO1993001303A1 (en) 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line
SE9200502 1992-07-03

Publications (3)

Publication Number Publication Date
FI935970A0 FI935970A0 (fi) 1993-12-31
FI935970L FI935970L (fi) 1993-12-31
FI109207B true FI109207B (fi) 2002-06-14

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935970A FI109207B (fi) 1991-07-03 1993-12-31 Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja

Country Status (19)

Country Link
US (1) US5552293A (hu)
EP (1) EP0521842B1 (hu)
JP (1) JP3194020B2 (hu)
KR (1) KR100246681B1 (hu)
AT (1) ATE171193T1 (hu)
AU (2) AU2292092A (hu)
CA (1) CA2073124C (hu)
DE (1) DE69226990T2 (hu)
DK (1) DK0521842T3 (hu)
EE (1) EE03031B1 (hu)
ES (1) ES2124250T3 (hu)
FI (1) FI109207B (hu)
HU (2) HU218084B (hu)
IE (1) IE80841B1 (hu)
IL (1) IL102390A (hu)
NO (1) NO315472B1 (hu)
NZ (1) NZ243435A (hu)
SE (1) SE9102074D0 (hu)
WO (2) WO1993001302A1 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
DK1411962T3 (da) 2001-03-15 2011-04-04 Neogenix Oncology Inc Terapi for pancreacancer med monoklonalt stof
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
NZ537610A (en) * 2002-07-02 2006-07-28 Smithkline Beecham Corp Stable formulations of the C242 antibody
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2004240541B2 (en) 2003-05-20 2009-08-20 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
EP2468304A3 (en) 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
JP2009505640A (ja) * 2005-08-11 2009-02-12 − ロジャーズ、アルピ マトシアン 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド
AU2012244244B2 (en) * 2005-08-11 2015-08-27 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
NZ716641A (en) 2005-08-24 2017-06-30 Immunogen Inc Process for preparing maytansinoid antibody conjugates
JP5644110B2 (ja) 2008-08-05 2014-12-24 東レ株式会社 癌の検出方法
DK2437790T3 (da) 2009-06-03 2019-05-20 Immunogen Inc Konjugeringsfremgangsmåder
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
CA2886993A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
CA2966932A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
CA3010678A1 (en) 2016-01-10 2017-07-20 Neotx Therapeutics Ltd. Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
KR20180105233A (ko) 2016-02-05 2018-09-27 이뮤노젠 아이엔씨 세포 결합제-세포독성제 접합체를 제조하기 위한 효율적인 방법
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
MX2021013908A (es) 2019-05-15 2022-03-11 Neotx Therapeutics Ltd Tratamiento para el cáncer.
MX2022010936A (es) 2020-03-05 2022-11-16 Neotx Therapeutics Ltd ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
JP3334130B2 (ja) * 1990-07-20 2002-10-15 フアルマシア・アクチエボラーグ 抗体接合体
EP0540612A1 (en) * 1990-07-20 1993-05-12 Pharmacia AB Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures

Also Published As

Publication number Publication date
AU2292092A (en) 1993-02-11
ES2124250T3 (es) 1999-02-01
WO1993001302A1 (en) 1993-01-21
WO1993001303A1 (en) 1993-01-21
DE69226990D1 (de) 1998-10-22
KR100246681B1 (ko) 2000-04-01
NO934777D0 (no) 1993-12-22
CA2073124A1 (en) 1993-01-04
AU658198B2 (en) 1995-04-06
NO315472B1 (no) 2003-09-08
EE03031B1 (et) 1997-08-15
DE69226990T2 (de) 1999-03-25
IL102390A0 (en) 1993-01-14
HU9400011D0 (en) 1994-05-30
HU218084B (hu) 2000-05-28
EP0521842A2 (en) 1993-01-07
CA2073124C (en) 2007-06-19
EP0521842B1 (en) 1998-09-16
JP3194020B2 (ja) 2001-07-30
FI935970A0 (fi) 1993-12-31
JPH05276987A (ja) 1993-10-26
NO934777L (no) 1994-02-11
SE9102074D0 (sv) 1991-07-03
IE80841B1 (en) 1999-03-24
HUT71193A (en) 1995-11-28
ATE171193T1 (de) 1998-10-15
IL102390A (en) 1996-01-19
US5552293A (en) 1996-09-03
NZ243435A (en) 1994-10-26
EP0521842A3 (hu) 1994-01-26
HU211512A9 (en) 1995-11-28
DK0521842T3 (da) 1999-06-14
FI935970L (fi) 1993-12-31
AU1942592A (en) 1993-01-07
IE922188A1 (en) 1993-01-13

Similar Documents

Publication Publication Date Title
FI109207B (fi) Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja
JP3492373B2 (ja) モノクローナル抗体
JP4124486B2 (ja) ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用
CN111777681B (zh) 一种结合紧密连接蛋白-18.2的抗体及其用途
JP2000511421A5 (hu)
JP2001501801A (ja) モノクローナル抗体ｂｒ１１０およびその使用
PT94565B (pt) Novos anticorpos reactivos com carcinomas humanos
JP2935520B2 (ja) ガン治療に用いられる新規高親和性改変抗体系統群
EP4257612A1 (en) Development of new tumor engager therapeutic drug and use thereof
IE60286B1 (en) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas
JP2007535907A (ja) 抗ヒドロキシラーゼ抗体およびその使用
CN115297890A (zh) 用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物
US20050003469A1 (en) Tumor specific human monoclonal antibodies and methods of use
CN114423790B (zh) 靶向caix抗原的纳米抗体及其应用
RU2268068C2 (ru) Новое антитело со специфичностью к злокачественной опухоли толстой кишки
AU2018237046B2 (en) Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
WO2021229104A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment
EP4149543A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: PHARMACIA AB

MA Patent expired